ObesityWeek 2026 | Retatrutide | Zepbound | CagriSema | Wegovy

Eli Lilly Unveils Broad Metabolic Data at ObesityWeek 2026 Highlighting Sleep Apnea, Joint Pain, and Combination Therapy
Eli Lilly is set to share new clinical and real-world findings across its weight management portfolio during ObesityWeek 2026. The presentations spotlight progress in treating broader health complications tied to excess weight, featuring updates on Zepbound, Foundayo, retatrutide, and eloralintide.
Combination Therapy Delivers Major Weight and Blood Sugar Drops
During an oral presentation on EloraTZP, an experimental pairing of eloralintide and tirzepatide, researchers will highlight notable Phase 2 outcomes in adults living with type 2 diabetes alongside obesity or excess weight.
Weight Reduction: Starting from an average baseline weight of 232.4 pounds, study volunteers lost up to an average of 54.1 pounds, or 23.3% of their body weight, after 48 weeks. Up to 60% of these individuals dropped below the body mass index threshold for obesity.
Blood Glucose Control: The combination therapy reduced A1C levels by up to an average of 2.9 percentage points, helping up to 77% of study participants reach normal blood sugar ranges.
Retatrutide Targets Sleep Apnea and Knee Pain
Clinical data from the TRIUMPH trial program demonstrate that retatrutide, an experimental triple hormone receptor agonist, eases two serious physical conditions often linked to obesity.
Obstructive Sleep Apnea: In the TRIUMPH-1 study, adults with obesity or excess weight and moderate-to-severe obstructive sleep apnea saw breathing interruptions drop by up to an average of 36.1 events per hour, a 60.6% reduction, at the 80-week mark. In TRIUMPH-2, which focused on patients who also had type 2 diabetes, breathing disruptions fell by up to an average of 28.4 events per hour, or 48.1%, over the same 80-week timeframe.
Knee Osteoarthritis: Pain scores measured on the Western Ontario and McMaster Universities Osteoarthritis Index fell significantly in two trials. In TRIUMPH-1, knee pain dropped by up to an average of 4.3 points, or 73.1%, at 80 weeks. In TRIUMPH-4, patients experienced up to an average 4.5-point drop, or 75.8% reduction, after 68 weeks.
Adolescent Progress with Zepbound
Results from the SURMOUNT-ADOLESCENTS study indicate strong outcomes for younger patients aged 12 to under 18. After 72 weeks of treatment with Zepbound, participants lowered their body mass index by an average of 21.4%. More than half of the adolescents in the trial no longer met the clinical criteria for obesity by the end of the period, and many noted better physical comfort and improved body image.
Real-World Convenience and Behavioral Shifts
Poster sessions at the conference will explore patient experiences with both oral and injectable treatments.
Foundayo Ease of Use: A real-world survey from the FOUNDERS study revealed that 96% to 98% of patients found the once-daily oral medication simple and convenient to take. Because the pill carries no food or water restrictions, most users took it alongside meals, drinks, or other daily pills, with roughly 40% preferring afternoon, evening, or bedtime dosing.
Portfolio Background of Eli Lilly within obesity, diabetes and obstructive sleep apnea
Zepbound (tirzepatide): An approved weekly injection that activates both GIP and GLP-1 hormone receptors to curb appetite and reduce food intake. It is prescribed alongside diet and exercise for chronic weight management in adults with obesity or weight-related health issues, as well as for adults with obesity and moderate-to-severe obstructive sleep apnea.
Foundayo (orforglipron): An approved daily non-peptide oral GLP-1 receptor agonist for long-term weight management in adults, designed for flexible dosing without meal or water restrictions. Originally discovered by Chugai Pharmaceutical and licensed by Lilly in 2018, the pill is also under investigation for type 2 diabetes, sleep apnea, knee pain, high blood pressure, peripheral artery disease, and stress urinary incontinence.
Retatrutide: An experimental weekly injection engineered to stimulate GIP, GLP-1, and glucagon receptors simultaneously. Currently in Phase 3 testing for weight management, type 2 diabetes, sleep apnea, knee osteoarthritis, chronic low back pain, liver disease, and heart and kidney outcomes, the drug remains unapproved for commercial sale.
Eloralintide: An experimental weekly selective amylin receptor agonist, formerly designated as LY3841136, designed to reduce calorie consumption by promoting fullness. It is undergoing Phase 3 trials for weight management in adults with or without type 2 diabetes, following Phase 2 testing evaluating it both as a standalone therapy and paired with tirzepatide.
Novo Nordisk CagriSema Data Shows 25% Mean Weight Reduction in Early Responders at ObesityWeek 2026
Novo Nordisk has shared fresh post hoc findings from its late-stage REDEFINE 1 study evaluating CagriSema, an experimental fixed-dose pairing of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide.
Early Weight Loss Predicts Deeper Long-Term Results
Researchers examined outcomes among patients receiving the 2.4 mg / 2.4 mg dose of CagriSema, categorizing individuals who shed at least 5% of their body weight by the eighth week as early responders. Roughly 67.8% of treated participants met this early milestone, with women representing a higher share of early responders compared to delayed responders at 71.8% versus 59.5%.
By week 68, observed weight reductions diverged noticeably between the two groups:
Overall Mean Weight Loss: Early responders achieved an average weight drop of 25.4% at week 68 (up from 7.8% at week 8), whereas delayed responders recorded an average reduction of 17.8% (up from 3.4% at week 8).
Achieving 20% or More Weight Loss: Nearly three-quarters (73.3%) of early responders lost at least 20% of their body weight by week 68, compared with 37.2% of delayed responders.
Moderate Reductions: Among early responders, 16.1% lost between 15% and under 20% of their body weight, 7.9% lost between 10% and under 15%, and 2.5% lost between 5% and under 10%, leaving only 0.3% below the 5% threshold. In the delayed responder cohort, 23.8% fell into the 15% to under 20% range, 21.3% reached 10% to under 15%, 14.0% hit 5% to under 10%, and 3.6% stayed under 5%.
Improvements in Daily Function and Quality of Life
A separate retrospective evaluation of REDEFINE 1 measured patient-reported outcomes at week 68 using the Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) assessment. Across every measured category, a substantially larger proportion of adults taking CagriSema experienced meaningful personal improvements compared with those on placebo:
Physical Function: 73.1% of CagriSema patients reported meaningful gains versus 49.1% in the placebo group.
Overall Physical Score: 73.4% saw improvements on CagriSema compared with 50.1% on placebo.
Psychosocial Well-Being: 69.0% achieved meaningful progress versus 42.1% receiving placebo.
Total Assessment Score: 69.1% of treated participants reached meaningful improvements compared with 40.4% in the control arm.



Comments